Becton Dickinson (BRSE:000912061) - Hisse Senedi Fiyatı, Haberler ve Analizler

000912061 Stoklara Genel Bakış

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. Daha fazla detay

000912061 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	3/6
Finansal Sağlık	3/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 44.1% daha düşük bir oranda işlem görüyor

Kazançların yılda 15.74% oranında artması öngörülüyor

Kazançlar geçen yıl 27.9% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

Borç işletme nakit akışı tarafından iyi karşılanmıyor

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Becton, Dickinson and Company Rakipler

Sonova Holding

SWX:SOON

CHF 19.0b

Straumann Holding

SWX:STMN

CHF 18.1b

Medacta Group

SWX:MOVE

CHF 2.3b

Alcon

SWX:ALC

CHF 37.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Becton Dickinson
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$238.02
52 Haftanın En Yüksek Seviyesi	US$253.43
52 Haftanın En Düşük Seviyesi	US$238.02
Beta	0.59
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-2.22%
33 Yıllık Değişim	-2.21%
5 Yıllık Değişim	26.81%
Halka arzdan bu yana değişim	94.30%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	000912061	CH Medical Equipment	CH Pazar
7D	0%	-3.3%	-1.1%
1Y	-2.2%	16.9%	8.2%

Getiri vs. Endüstri: 000912061 geçen yıl % 16.9 oranında getiri sağlayan Swiss Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: 000912061 geçen yıl % 8.2 oranında getiri sağlayan Swiss Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 000912061's price volatile compared to industry and market?
000912061 volatility
000912061 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	6.9%
10% least volatile stocks in CH Market	1.6%

İstikrarlı Hisse Senedi Fiyatı: 000912061 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 000912061 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1897	75,000	Tom Polen	www.bd.com

Becton, Dickinson and Company Temel Bilgiler Özeti

Becton Dickinson'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
000912061 temel i̇stati̇sti̇kler
Piyasa değeri	CHF 65.43b
Kazançlar(TTM)	CHF 1.86b
Gelir(TTM)	CHF 19.69b

35.1x

F/K Oranı

3.3x

P/S Oranı

000912061 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
000912061 gelir tablosu (TTM)
Gelir	US$20.08b
Gelir Maliyeti	US$10.59b
Brüt Kâr	US$9.49b
Diğer Giderler	US$7.59b
Kazançlar	US$1.90b

Son Raporlanan Kazançlar

Jun 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	6.66
Brüt Marj	47.25%
Net Kâr Marjı	9.46%
Borç/Özkaynak Oranı	64.2%

000912061 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.5%

Mevcut Temettü Verimi

52%

Ödeme Oranı

000912061 Stoklara Genel Bakış

Ödüller

Risk Analizi

Becton, Dickinson and Company Rakipler

SWX:SOON

CHF 19.0b

SWX:STMN

CHF 18.1b

SWX:MOVE

CHF 2.3b

SWX:ALC

CHF 37.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Recent updates

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes